|
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
Companies mentioned in this article: Celgene Corporation SUMMIT, N.J.-- (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
- Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals - REVLIMID Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q - VIDAZA Fourth Quarter Global Net Product...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $761 Million Global REVLIMID Net Product Sales Increased 35...
|
|
|
Celgene reports total revenue of $758M for fourth-quarter of 2009
Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $761 Million Global REVLIMID Net Product Sales Increased 35 Percent to $497 Million Global VIDAZA Net Product Sales Increased 68 Percent to $117 Million Global THALOMID Net...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
SUMMIT, N.J.- (BUSINESS WIRE) - Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $761 Million Global REVLIMID Net Product Sales Increased...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
- Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals - REVLIMID Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q - VIDAZA Fourth Quarter Global Net Product...
|
|
|
Celgene Sees 4Q Profit On Sales Boost, Lower Costs
SUMMIT, N.J.--Biotech drugmaker Celgene Corp.on Thursday reported a fourth-quarter profit on a boost in sales of the cancer drugs Revlimid and Vidaza, along with lower research and development costs. The Summit, N.J. company earned $254.2 million, or 54...
|
|
|
Celgene reports 4th-quarter profit on cancer drug sales boost, lower research costs
SUMMIT, N.J.Biotech drugmaker Celgene Corp. on Thursday reported a fourth-quarter profit on a boost in sales of the cancer drugs Revlimid and Vidaza, along with lower research and development costs. The Summit, N.J. company earned $254.2 million, or 54...
|
|
|
Celgene Corporation (NASDAQ:CELG) Acquires Cloucester Pharmaceuticals
Rochester, New York 1/18/2010 09:30 PM GMT (TransWorldNews) Celgene Corporation (NASDAQ:CELG) has announced that it has acquired Gloucester Pharmaceuticals.The transaction closed for $340 million, after the early termination of the applicable waiting period...
|
|
|
Celgene completes acquisition of Gloucester Pharma
Celgene Corporation has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of the merger agreement Celgene...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
SUMMIT, N.J.-- (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements...
|
|
|
Celgene completes acquisition of Gloucester Pharmaceuticals
--Celgene Corporation announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of the merger...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 million Commercial Launch of Novel HDAC Inhibitor, ISTODAX (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
(Source: Business Wire)Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 million Commercial Launch of Novel HDAC Inhibitor, ISTODAX (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
SUMMIT, N.J.- (BUSINESS WIRE) - Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 million Commercial Launch of Novel HDAC Inhibitor, ISTODAX (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Celgene Corporation CELG today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of the merger...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG - News) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG - News) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust...
|
|
|
Advances in Optimizing Therapy and Quality of Life for People With Hard-to-Treat Blood Cancers
Research presented at the 51st Annual ASH Meeting explored optimal induction therapies for managing multiple myeloma and a potential first-line therapy for patients with non-Hodgkin lymphoma (NHL).Studies such as these are designed to improve the quality of...
|
|
|
Addition of Velcade and Revlimid to Autologous Stem Cell Transplantation Produces Promising Results in Older Patients with Multiple Myeloma
In a Phase II clinical trial, treatment of older multiple myeloma patients with Velcade (bortezomib) induction therapy, reduced-intensity tandem autologous stem cell transplantation, and Revlimid (lenalidomide) consolidation-maintenance therapy produced...
|
|
|
EntreMed Reports Receipt of Third Quarter Royalty Payment
ROCKVILLE, Md., Dec.11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the receipt of $1.7 million in royalty revenue from sales of Thalomid during the third quarter compared to estimated royalty revenue of $3.3 million. In...
|
